
COVID-19 pandemic catalyses real-world oncology data uptake
03 August 2022
- “By necessity, COVID-19 has pushed the cancer clinical trial community out of its comfort zone to rapidly deploy remote assessments and digital health technology, [prompting] unprecedented collaboration to explore the use of real-world data. We cannot lose this opportunity to learn and advance our knowledge of the strengths and limitations of decentralized trials and real-world data to move our cancer research enterprise to a more efficient and more patient-friendly model.”
- “We’ve witnessed a great interest in taking advantage of real-world data to rapidly expand our knowledge of the natural history of disease and treatment,” Paul G. Kleutz (Deputy Director of the Oncology Centre for Excellence, FDA)